{
    "clinical_study": {
        "@rank": "23281", 
        "arm_group": [
            {
                "arm_group_label": "Docosahexaenoic acid administration", 
                "arm_group_type": "Experimental", 
                "description": "50 patients will receive docosahexaenoic acid"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "50 patients will receive placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Cystic Fibrosis (CF) is a congenital disease secondary to the abnormal function of CFTR.\n      Patients with CF have an alteration of essential fatty acids, Arachidonic Acid (AA) is\n      increased and Docosahexanoic Acid (DHA) is decrease and the ratio \u03c9-6/ \u03c9-3 is elevated, all\n      these alterations stimulated a chronic and bad regulated state of inflammation. For this\n      porpoise, a fase IV trial, multicentric, controlled, double blind, placebo and parallel in\n      patients elder than two months old and randomized to received every day a dietetically\n      supplement with DHA or placebo, will be done during 12 months. The trial has as a principal\n      objective to proved if this long term supplementation could decrease in contrast with\n      placebo."
        }, 
        "brief_title": "Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic Fibrosis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed of cystic fibrosis over than 2 months age\n\n          -  Tolerance clinical supplementation with DHA\n\n          -  Clinical situation stable\n\n        Exclusion Criteria:\n\n          -  Changes in the routine treatment in the 2 weeks prior to baseline\n\n          -  Admission to hospital or administration of oral or intravenous antibiotics within 2\n             weeks before inclusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783613", 
            "org_study_id": "Docosahexaenoic acid"
        }, 
        "intervention": [
            {
                "arm_group_label": "Docosahexaenoic acid administration", 
                "intervention_name": "Docosahexaenoic acid administration: 50 mg/kg/day during 12 months", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Placebo: 50 mg/kg/day during 12 months", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "state": "Asturias", 
                        "zip": "33006"
                    }, 
                    "name": "Hospital Universitario Central de Asturias"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Ram\u00f3n y Cajal Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Hospital 12 de Octubre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitario La Princesa"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46026"
                    }, 
                    "name": "Hospital Universitari i Politecnic La FE"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of the Eficacy of Long-term Suplementation With Docosahexaenoic Acid on Pulmonary, Sistemic and Intestinal Inflammation in Patients With Cystic Fibrosis", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To study whether  long-term administration of DHA (12 months), at doses of 50 mg/ kg/day in patients over 2 months age diagnosed of CF decreases inflammation compared with placebo", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}